Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trialsColin Baigent, Faı̈ez Zannad, Natalie Staplin et al.|The Lancet|2022Cited by 969
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysisBrendon L. Neuen, Meg Jardine, T. Kue Young et al.|The Lancet Diabetes & Endocrinology|2019Cited by 870
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trialsEllen M. Apperloo, Hiddo J.L. Heerspink, Brendon L. Neuen et al.|The Lancet Diabetes & Endocrinology|2024Cited by 135
Cardiovascular, kidney, and metabolic health: an actionable vision for heart failure preventionJohn W. Ostrominski, Muthiah Vaduganathan, Alice Cheng et al.|The Lancet|2025Cited by 15
EFFECTS OF SGLT2 INHIBITORS ON CARDIOVASCULAR OUTCOMES WITH AND WITHOUT BASELINE USE OF GLP-1 RECEPTOR AGONISTS: A SMART-C COLLABORATIVE META-ANALYSISBrendon L. Neuen, Hiddo J.L. Heerspink, Ellen M. Apperloo et al.|Journal of the American College of Cardiology|2024Cited by 1